Texas clocks in as 5th hardest-working state in U.S., survey says

LAUDING TEXAS’ LABOR FORCE

We work hard for the money in Houston. Photo by Hinterhaus Productions/Getty

n the 1980s, disco queen Donna Summer sang the praises of a blue-collar woman in the hit tune “She Works Hard for the Money.” If the song were to be updated for this decade, it might morph into an ode to the hardworking women and men of Texas.

A new ranking from personal finance website WalletHub puts Texas at No. 5 among the hardest-working states. The Lone Star State repeated its fifth-place showing from last year. In the 2022 study, Texas is preceded by North Dakota, Alaska, Nebraska, and South Dakota. The slackers, it appears, are in bottom-ranked New Mexico.

WalletHub evaluated each state based on 10 metrics. In the Labor Day-timed study, Texas earned an especially high mark for the average number of hours worked per week (ranked fourth).In July 2022, nearly 14.6 million people were part of the state’s civilian workforce (which excludes active-duty military personnel), according to the U.S. Bureau of Labor Statistics. That month, the state’s unemployment rate stood at 4 percent.

In a news release touting the July 2022 job numbers for Texas, Gov. Greg Abbott highlighted the state’s “young, skilled, diverse, and growing workforce.”

“Texas jobs are booming, and more Texans are working than ever before as we again break all previous records for total jobs,” Abbott says. “Despite the economic challenges job creators are facing across the nation, businesses are investing with confidence in the Lone Star State because we’ve built a framework that allows free enterprise to flourish and hardworking Texans to succeed.”

------

this article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”